Stephens Inc. AR decreased its position in shares of Cigna Corp (NYSE:CI) by 4.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,055 shares of the health services provider’s stock after selling 209 shares during the quarter. Stephens Inc. AR’s holdings in Cigna were worth $639,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. C J Advisory Inc acquired a new position in shares of Cigna during the first quarter valued at $40,000. TRUE Private Wealth Advisors acquired a new stake in Cigna in the second quarter worth about $40,000. Trustcore Financial Services LLC acquired a new stake in Cigna in the first quarter worth about $49,000. Baldwin Brothers Inc. MA acquired a new stake in Cigna in the first quarter worth about $50,000. Finally, Close Asset Management Ltd acquired a new stake in Cigna in the first quarter worth about $55,000. 87.64% of the stock is owned by institutional investors.
Shares of NYSE CI opened at $162.34 on Thursday. Cigna Corp has a twelve month low of $141.95 and a twelve month high of $226.60. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $61.54 billion, a price-to-earnings ratio of 11.42, a PEG ratio of 0.83 and a beta of 0.70. The firm has a 50-day moving average of $168.05 and a two-hundred day moving average of $165.49.
Several research firms recently weighed in on CI. ValuEngine downgraded shares of Cigna from a “hold” rating to a “sell” rating in a report on Tuesday, July 23rd. Goldman Sachs Group downgraded shares of Cigna from a “conviction-buy” rating to a “buy” rating in a report on Friday, May 3rd. Morgan Stanley reduced their price objective on shares of Cigna from $241.00 to $207.00 and set an “overweight” rating for the company in a report on Friday, July 12th. Raymond James upped their price objective on shares of Cigna from $185.00 to $190.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Finally, Zacks Investment Research downgraded shares of Cigna from a “buy” rating to a “hold” rating and set a $164.00 price objective for the company. in a report on Tuesday, June 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $214.55.
Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.
Recommended Story: What are retained earnings?
Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cigna Corp (NYSE:CI).
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.